Cancer Family
Neuroendocrine Neoplasm
CI-CAN-00000286NENExplore in graph →
Non-malignant700 active trials12 approved drugs34 evidence items
- NCIt
- C3809
Loading cancer entity…
Cancer Family
CI-CAN-00000286NENExplore in graph →
Clinical trials
2,395 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04569591 | DDAVP for Pituitary Adenoma | recruiting | N/A | 22 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05048901 | Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors | recruiting | Phase 1 / Phase 2 | 49 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06141369 | Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) | recruiting | N/A | 21 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07520357 | A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinoma | not yet recruiting | Phase 2 | 23 | Beijing GoBroad HospitalOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT04660097 | Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer | completed | Phase 2 | 34 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04869137 | Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma | active not recruiting | Phase 2 | 26 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04919382 | Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer | recruiting | Phase 2 | 56 | Dwight OwenOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07518602 | Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma | recruiting | Phase 2 | 34 | Sun Yat-sen UniversityOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04560972 | LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer | active not recruiting | Phase 1 | 3 | City of Hope Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04792073 | Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma | active not recruiting | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07424547 | Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 386 | Conjupro Biotherapeutics, Inc.INDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07516275 | Prospective Cohort Study of Pheochromocytoma/Paraganglioma | not yet recruiting | — | 200 | Peking Union Medical College HospitalOTHER | 0 | Apr 7, 2026 | clinicaltrials |
| NCT04709276 | A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer(CHAMP) | active not recruiting | Phase 2 | 41 | Andrew J. Armstrong, MDOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05703269 | Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy(HYPOGRYPHE) | active not recruiting | N/A | 58 | Wake Forest University Health SciencesOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT04256421 | A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer(SKYSCRAPER-02) | completed | Phase 3 | 490 | Hoffmann-La RocheINDUSTRY | 23 | Apr 3, 2026 | clinicaltrials |
| NCT07510594 | A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC | not yet recruiting | Phase 2 | 48 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07510724 | Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab(IKF-ReWoLuTe) | recruiting | — | 240 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 2 | Apr 3, 2026 | clinicaltrials |
| NCT06840704 | Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer(Relief) | recruiting | Phase 3 | 121 | Hunan Cancer HospitalOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03923270 | Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer | active not recruiting | Phase 1 | 25 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04069299 | Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract | completed | — | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04607954 | Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer | active not recruiting | Phase 2 | 29 | Mayo ClinicOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07015892 | Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial(ESCALADOR) | recruiting | Phase 3 | 300 | Instituto de Investigación Biomédica de SalamancaOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05477576 | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy(ACTION-1) | recruiting | Phase 3 | 338 | RayzeBio, Inc.INDUSTRY | 8 | Mar 30, 2026 | clinicaltrials |
| NCT06424067 | Phase 2 Study of Fingolimod in Lung Cancers | recruiting | Phase 2 | 38 | Medical University of South CarolinaOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06769126 | Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study | recruiting | Phase 2 | 900 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06826170 | Hypofractionated Radiosurgery to Treat Residual/Recurrent Non Secreting Pituitary Adenoma (HYPOADENO)(HYPOADENO) | completed | N/A | 25 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07489339 | MDT-Based Nursing for Small Cell Lung Cancer During Chemo-Immunotherapy(SCLC-MDT) | completed | N/A | 200 | Shanxi Province Cancer HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07501650 | Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer | recruiting | Phase 1 | 6 | Thomas Jefferson UniversityOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 115 | SOTIO Biotech AGINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT04261855 | Targeted Therapy and Avelumab in Merkel Cell Carcinoma(GoTHAM) | active not recruiting | Phase 1 / Phase 2 | 19 | Melanoma and Skin Cancer Trials LimitedOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04450043 | The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance | active not recruiting | N/A | 21 | Massachusetts General HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07055581 | Durvalumab as Consolidation for Patients LS-SCLC | recruiting | Phase 2 | 100 | Qian ChuOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07276360 | Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda(HypoRTCx-UG) | recruiting | Phase 2 | 278 | Uganda Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05847855 | Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors | recruiting | — | 1,000 | Fudan UniversityOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06008977 | Exercise to Boost Response to Checkpoint Blockade Immunotherapy(EX-BOOST) | active not recruiting | N/A | 12 | AdventHealth Translational Research InstituteOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04074642 | OCT-angiography as a Pronostic Marker for Visual Impairment in Patients Undergoing Neurosurgery for Compressive Macroadenoma : a Prospective Study.(FIRST) | completed | N/A | 21 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT05680922 | DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer | active not recruiting | Phase 1 | 41 | Legend Biotech USA IncINDUSTRY | 1 | Mar 24, 2026 | clinicaltrials |
| NCT04804371 | Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors | active not recruiting | N/A | 40 | University Health Network, TorontoOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04090034 | Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors(PRRT) | recruiting | — | 50 | Methodist Health SystemOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07485920 | A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer | not yet recruiting | Phase 4 | 20 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04211337 | A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer(LIBRETTO-531) | active not recruiting | Phase 3 | 291 | Loxo Oncology, Inc.INDUSTRY | 20 | Mar 19, 2026 | clinicaltrials |
| NCT05361668 | Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome | completed | Phase 2 | 36 | Crinetics Pharmaceuticals Inc.INDUSTRY | 7 | Mar 19, 2026 | clinicaltrials |
| NCT05411133 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | completed | Phase 1 | 33 | Arbele Pty LtdINDUSTRY | 2 | Mar 19, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480213 | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)(DART-NK-SCLC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | recruiting | Phase 1 | 18 | Anusha KalbasiOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04802174 | Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers | active not recruiting | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05746208 | Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors | recruiting | Phase 2 | 29 | University of California, San FranciscoOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07001995 | Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression | not yet recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07472647 | SYS6090 Combination Therapy in Advanced Lung Cancer | not yet recruiting | Phase 1 / Phase 2 | 596 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Mar 16, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 9, 2026source: clinicaltrials